The pharmacological blockade of αv‐containing integrins by cilengitide inhibits TGFβ1 signalling and produces the desired antifibrotic effects without the potential side effects of blocking pan‐TGFβ1, such as autoimmunity and carcinogenesis.7 Here, TGFB1 is linked to Autoimmunity.